Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | APEX1 | P27695 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | P2RY14 | Q15391 | 5/20 | 0.52 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.52 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.52 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.52 |
| ▸ | OGT | O15294 | 2/20 | 0.46 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.45 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.45 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.45 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30438116 | 1.00 | MEN1 (0.59) | MEN1APEX1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL25269457 | 1.00 | MEN1 (0.59) | MEN1APEX1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL3738697 | 1.00 | MEN1 (0.59) | MEN1APEX1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL25251763 | 1.00 | MEN1 (0.59) | MEN1APEX1KMT2AMAPTSMN1; SMN2 | |
| Tunicamycin SCHEMBL29352796 | 0.96 | MEN1 (0.55) | MEN1APEX1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL20412283 | 0.94 | MEN1 (0.52) | MEN1APEX1KMT2AMAPTSMN1; SMN2 | |
| Tunicamycin B SCHEMBL21597944 | 0.91 | MEN1 (0.72) | MEN1APEX1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL21597951 | 0.91 | MEN1 (0.72) | MEN1APEX1KMT2AMAPTSMN1; SMN2 | |
| Streptovirudin B2A SCHEMBL21597942 | 0.91 | MEN1 (0.72) | MEN1APEX1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL21597940 | 0.91 | MEN1 (0.72) | MEN1APEX1KMT2AMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9428541-B2 | Substrate reduction therapy | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2016-08-30 | — | — | US | disclosed |
| US-20140080769-A1 | SUBSTRATE REDUCTION THERAPY | THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD (GB) | 2014-03-20 | — | — | US | disclosed |
| US-8557844-B2 | Substrate reduction therapy | THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD (GB) | 2013-10-15 | — | — | US | disclosed |
| US-20100204162-A1 | SUBSTRATE REDUCTION THERAPY | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2010-08-12 | — | — | US | disclosed |
| US-20100022620-A1 | EPITOPE REDUCTION THERAPY | ISIS INNOVATION LIMITED (GB) | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204162-A1 | SUBSTRATE REDUCTION THERAPY | GBA1, SPTLC2, NPC1L1 | MEN1 2550/4885APEX1 2870/4885KMT2A 1611/4885 |
| US-20140080769-A1 | SUBSTRATE REDUCTION THERAPY | GBA1, SPTLC2, NPC1L1 | MEN1 2550/4885APEX1 2870/4885KMT2A 1611/4885 |
| US-20100022620-A1 | EPITOPE REDUCTION THERAPY | UGCG, GBA1, ENGASE | MEN1 2963/4885APEX1 1959/4885KMT2A 2152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.